Title:
【発明の名称】中枢神経系リンパ腫治療用のリツキシマブのクモ膜下投与
Document Type and Number:
Japanese Patent JP2003531178
Kind Code:
A
Abstract:
This invention describes methods of using anti-B cell antibodies, preferably anti-CD20 antibodies, and most preferably Rituximab, to treat B cell lymphomas of the brain, especially primary central nervous system lymphomas (PCNSLs), and to prevent meningeal relapse. The antibodies can be administered intrathecally alone, or in combination with other chemotherapeutics, such as methotrexate, or other anti-B cell antibodies to treat PCNSL in both immunocompromised and non-immunocompromised patients. These antibodies can also be used to diagnose patients with CNS lymphoma, especially in immunocompromised patients.
Inventors:
Grillo-Lopez, Antonio, Jay
Application Number:
JP2001577981A
Publication Date:
October 21, 2003
Filing Date:
April 25, 2001
Export Citation:
Assignee:
IDEC Pharmaceuticals Corporation
International Classes:
A61K51/00; A61K31/519; A61K31/675; A61K31/7068; A61K38/00; A61K39/395; A61K51/10; A61P35/00; C07K16/28; (IPC1-7): A61K39/395; A61K31/519; A61K31/675; A61K31/7068; A61K38/00; A61K51/00; A61P35/00
Attorney, Agent or Firm:
Akira Asamura (3 outside)